Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATORM-E
- Development stage
- Preclinical
- Lead developer
- OrganoidSciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
ATORM-E is an endometrium (uterine) organoid-based regenerative cell therapy being developed by OrganoidSciences. It is designed to treat endometrial and uterine disorders, specifically Asherman's syndrome (uterine adhesion). The therapy utilizes three-dimensional organoids derived from adult stem cells of the endometrium, which are transplanted locally to promote the regeneration and functional recovery of damaged uterine tissue. Currently, ATORM-E is in the preclinical stage of development, undergoing efficacy and optimization evaluations.
- Other names
- Endometrium organoid regenerative therapeuticUterine organoid regenerative therapeutic
Beyond the preview
Go deeper on ATORM-E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATORM-E.